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ABSTRACT 
REPRODUCTIVE FACTORS AND POSTMENOPAUSAL FOLLICLE 
STIMULATING HORMONE LEVELS  
 
MAY 2020 
 
REBECCA COSTA, B.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Professor Elizabeth Bertone-Johnson 
 
Recent studies have shown that postmenopausal follicle stimulating hormone 
(FSH) levels may be predictive of future cardiovascular disease risk. However, little is 
known about postmenopausal FSH levels, including the level of variation between 
women and factors associated with this variation. We assessed the relationship of 
multiple reproductive factors with FSH levels among 588 postmenopausal women in the 
Kuopio Ischemic Heart Disease Risk Factor Study. Participants were aged 53 to 73 years 
and not using hormone therapy at baseline (1998-2001). Reproductive factors were 
assessed at baseline, along with FSH levels. After adjustment for sex steroids, adiposity 
measures, plasma lipids, blood pressure, and behavioral factors, we observed that women 
with 3 or more births and an age at first birth of 25 or later had mean FSH levels that 
were significantly 7.6 IU/L lower than those of women with a 1 to 2 births and an age at 
first birth of 24 or less. Number of miscarriages was inversely correlated with FSH levels. 
Women reporting a 7 or more years of OC use and 4-6 or 7 or more years of HT use each 
had significantly higher mean FSH levels than women who had never used OCs or HT. In 
summary, multiple reproductive factors were associated with postmenopausal FSH 
levels, independent of estradiol, adiposity, and other factors. These findings warrant 
replication and further exploration of potential underlying mechanism. 
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CHAPTER 1 
INTRODUCTION 
Recent studies have shown that postmenopausal follicle-stimulating hormone 
(FSH) levels may be inversely associated with prevalence of diabetes and atherosclerosis 
in postmenopausal women.1,2 Findings from these studies suggest that postmenopausal 
FSH levels may be predictive of future cardiovascular disease risk. However, little is 
known about postmenopausal FSH levels, including the level of variation between 
women and the factors associated with this variation. Given the important role of FSH in 
follicle development and ovulation in premenopausal women, we hypothesized that 
reproductive history may be associated with postmenopausal FSH levels.3  
 Follicle-stimulating hormone is involved in menstrual cycle regulation and 
fluctuates cyclically during the premenopausal years via feedback with estradiol.3 The 
release of FSH by the anterior pituitary stimulates the production of estradiol in the 
ovarian follicles. As the follicles mature, estrogen levels rise, creating a negative 
feedback effect with the anterior pituitary and causing FSH level to decline. After 
estrogen levels decline at the end of the cycle, this negative feedback is broken, and the 
cycle repeats.  
As menopause approaches and follicular estradiol production declines, FSH levels 
increase in order to maintain estrogen levels, although the level of increase in FSH 
around the time of the final menstrual period varies among women.4  Previous studies 
have shown that that there are three distinct trajectories of FSH change during the 
menopausal transition, including low, medium, and high rising. At the conclusion of the 
menopausal transition, FSH levels are believed to plateau and gradually decline.1,4 Very 
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little is known concerning FSH function in the years after the menopause transition is 
complete, though FSH secretion continues and levels between women vary substantially.  
Few studies have assessed whether reproductive factors including parity, 
pregnancy loss, age at first birth, exogenous hormone use, and gynecologic surgeries may 
be associated with postmenopausal FSH levels.  One study of 173 sedentary, overweight 
postmenopausal women found that nulliparous women had higher FSH levels than parous 
women,5 while a study of 270 healthy postmenopausal women found a positive 
association between pregnancy termination and FSH.6 The association of other 
reproductive factors with FSH, and likelihood of potential confounding by estrogens and 
other hormones, have not been investigated. Thus, we evaluated the relation of multiple 
reproductive factors and postmenopausal FSH while accounting for other factors 
including adiposity, hormones, and behavioral factors among a population of Finnish 
women. 
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CHAPTER 2 
METHODS 
2.1 Study Population 
 The KIHD study is an ongoing population-based cohort study of risk factors 
for cardiovascular and metabolic conditions in men and women living in eastern Finland. 
Whereas male participants were enrolled in 1984 to 1989, female participants were first 
enrolled between March 1998 and February 2001. Women eligible for enrollment were a 
random sample of 1173 postmenopausal women living in Kuopio and surrounding rural 
communities. Women from four specific age groups were selected: 53-56 years, 59-62 
years, 64-68 years, and 71-73 years. Of eligible women, 920 (78.4%) completed baseline 
clinical assessments and joined the cohort. Among the nonparticipants, 168 refused 
participation, 51 could not be contacted, and 34 were not included for other reasons. The 
study protocol was approved by the Research Ethics Committee of the University of 
Kuopio. All participants provided written informed consent.  
 
2.2 Questionnaire Assessments 
Participants reported data on demographic, behavior, reproductive, and health-
related factors on questionnaires, which were then reviewed by a trained interviewer for 
completeness and clarity. Reproductive factors included age at menarche, history and 
duration of oral contraceptive use, number of full-term pregnancies, age at last menses, 
and history of hysterectomy and oophorectomy; use of hormone therapy (HT; ever use, 
current use and total duration) was also assessed. Postmenopausal status and age at 
menopause were defined by the absence of menses for at least 12 months, or at the time 
of oophorectomy for women who reported having undergone surgery prior to menopause. 
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Physical activity was assessed with the KIHD 12-Month Leisure Time Physical Activity 
History questionnaire and was used to estimate amount of physical activity (metabolic 
equivalent of task hours) per day. Each participant also completed a detailed alcohol use 
questionnaire which was used to estimate alcohol intake. 
 
2.3 Blood Collection and Biochemical Measurements  
At the clinical interview, fasting blood samples were collected between 8:00 AM 
and 10:00 AM, after participants had abstained from eating or smoking cigarettes for 12 
hours and consuming alcohol for 3 days.2 Plasma was separated from other blood 
components within 60 minutes and stored at −20°C or−80°C until assay. Samples were 
assayed for FSH between June 2001 and February 2002. Serum FSH concentration was 
determined with a sandwich technique applying an immunoradiometric assay 
manufactured by Diagnostic Products Corporation (Coat-A-Count FSH IRMA; 
Diagnostic Products Corporation, Los Angeles, California). Serum 17-B-estradiol was 
assayed between 1999 and 2001 with a radioimmunoassay manufactured by DiaSorin 
(DiaSorin S.p.A., Stillwater, Minnesota). Serum testosterone (17B-hydroxy-4-androsten-
3-one) was determined with the Spectria Testosterone radioimmunoassay kit (Orion 
Diagnostic, Espoo, Finland). I label measurements for FSH, E2, and testosterone were 
carried out by gamma counter Wallac 1261 MultiGamma using a RiaCalc LM Evaluation 
Program. Coefficients of variation (CVs) were 5% for FSH, 7.6% to 12.0% for E2, and 
7.9% to 12.2% for testosterone.  
 Samples from all participants were assayed for high-density lipoprotein (HDL) 
and low-density lipoprotein (LDL) cholesterol, and triglycerides using laboratory 
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methods described in detail previously. CVs were 5.2% for LDL, 9.2% for HDL, and 
1.9% for triglycerides.  
 
2.4 Clinical Measures 
At baseline, resting systolic and diastolic blood pressure were calculated as the 
average of six measurements, including three made supine after 5 minutes resting; one 
made standing; and two made sitting, with 5 minutes between measures. Height and 
weight were directly measured and used to calculate BMI (weight in kg/square of height 
in m). Waist and hip circumferences were measured with a standard measuring tape and 
used to calculate waist-to-hip ratio. All measurements were then repeated at the follow-
up visit.  
 
2.5 Statistical Analysis 
The present analysis was limited to women not using HT at baseline (n=593). 
Additionally, five participants did not have FSH measurements and were excluded, 
leaving 588 women as the analytic population. 
FSH was normally distributed and did not require transformation. We divided the 
participants by age based on the categories used for participant recruitment (53-56, 59-62, 
64-68, 71-73) and compared mean FSH levels between the four categories using analysis 
of variance (ANOVA).  
To determine if participant characteristics were related to FSH levels, we 
evaluated these associations using linear regression. We then used linear regression to 
assess how reproductive factors, including number of full-term births, history of 
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spontaneous abortion, timing of first pregnancy, age at menarche, age at menopause, 
number of reproductive years, OC use and duration, past HT use and duration, and 
gynecologic surgical history (i.e., oophorectomy and hysterectomy), were associated with 
FSH. Indictor variables were created for fixed categories. To account for confounding by 
demographic, hormonal and behavioral factors, we built two multivariate models. In the 
first, we adjusted for year of study entry, age, enrollment age category ,estradiol, 
testosterone, and SHBG. Model 3 included model 2 variables plus current smoking, pack-
years of smoking, physical activity, alcohol use (g/week), waist:hip ratio, BMI, systolic 
and diastolic blood pressure, triglycerides, and LDL and HDL cholesterol. Information on 
variable categorizations are included in table footnotes.  
We then conducted stratified analyses to evaluate whether associations between 
reproductive factors and FSH levels varied by age (53-62 versus 64-73 years) and BMI 
(normal weight, overweight, obese).   
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CHAPTER 3 
RESULTS 
 The distribution of FSH by participant age group is presented in Table 1. Younger 
postmenopausal women (ages 53-56 years) had modestly higher mean FSH levels than 
older women (ages 71-73 years), although the means were not significantly lower among 
older women. Within each each group, there was a large variation in FSH levels. As 
shown in table 2, FSH levels were inversely associated with age, BMI, and waist-to-hip 
ratio, but were not associated with physical activity, alcohol intake, and smoking. FSH 
was significantly inversely associated with systolic blood pressure, estradiol, and 
testosterone, and significantly positively associated with plasma lipids and SHBG.  
 Association of pregnancy-related reproductive factors with FSH levels are 
presented in Table 3. In unadjusted analyses, mean age at first birth was inversely 
associated with FSH level. Women with a higher parity had lower FSH levels than 
women of a lower parity (model 1; P for trend 0.006). In the evaluation of age at first 
birth and parity simultaneously, both factors appeared to be independently inversely 
associated with FSH. Adjustment for sex steroids and SHBG attenuated results (model 2), 
but mean FSH levels remained significantly lower in women with three or more 
pregnancies and a later age at first birth than the reference groups (women with 1-2 births 
and first birth at <25 years). After additional adjustment for adiposity, behavioral, and 
clinical factors (model 3), a significant inverse trend for remained for parity and was 
suggestive for age at first birth. In the analysis of both factors simultaneously, mean FSH 
levels were significantly 7.6 IU/L lower among women with 3 or more births and first 
birth at age 25 or later.  The reported number of miscarriages among participants ranged 
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from 0 to 5, with n=104 women reporting 1 and n=30 reporting 2 or more miscarriages. 
Number of miscarriages was inversely associated with FSH level in each set of models.  
 Table 4 presents results on the relation of gynecologic surgeries and benign 
gynecologic conditions with FSH levels. History of hysterectomy, but not oophorectomy, 
was significantly inversely associated with FSH level in our unadjusted analysis. Women 
with a history uterine myoma had lower FSH levels than women who did not, while a 
history of endometriosis was not associated with FSH levels. Results for all of these 
relations were attenuated and no longer significant after adjustment for sex steroids and 
SHBG (model 2) and in our fully adjusted model (model 3).  
Associations of FSH levels with age at menarche and menopause, along with 
exogenous hormone use, are presented in Table 5. Age at last menses and age at 
menarche were not significantly associated with FSH level. Women with a history of HT 
use had higher FSH levels than women without HT use, with evidence of a dose-response 
relationship with duration of use. Women with the longest duration of OC use had higher 
FSH levels than women who never used OC, although no dose-response relationship was 
evident. Adjustment for sex steroids and SHBG (model 2) attenuated results, but mean 
FSH levels remained significantly higher for a long duration of HT use, and non-
significantly higher with a longer duration of OC use. In our fully adjusted model (model 
3), women reporting OC use for 7 or more years had significantly higher mean FSH 
levels than women who had never used OCs. Women who used HT for 4-6 years or 7+ 
years both had a significantly higher mean FSH levels than women who had never used 
HT. Age at menarche and last menses remained unassociated with FSH levels. 
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 To determine if associations between the main reproductive factors and FSH 
differed between younger and older postmenopausal women, we stratified women by age 
group (ages 53-62 years vs. 64-73 years) and reran our fully adjusted model (Table 6). In 
the evaluation of age at first birth and parity simultaneously, associations for higher 
parity and higher age at first birth were strong and significant among younger 
postmenopausal women, but not among older postmenopausal women. Long duration of 
OC use was similarly associated with higher FSH levels in both young and older women. 
Similarly, longer duration of HT use was positively associated with FSH levels in 
younger and older women, though a dose-response relation was not observed, likely due 
to low power for these comparisons.  
Because associations of reproductive factors with FSH levels could potentially be 
modified by adiposity, we then stratified our population according to World Health 
Organization BMI category (<25.0 (normal weight), 25.0-29.0 (overweight) or ≥ 30.0 
(obese). We did not observe evidence of effect modification by BMI for any of the 
factors evaluated.  
 
 
 
 
 
 
10 
 
CHAPTER 4 
DISCUSSION 
 In this study of older postmenopausal women, we observed significant 
associations between several reproductive factors and FSH levels. Women with both a 
high parity (3 or more births) and a later age at first birth (25 or later) had mean FSH 
levels that were significantly 7.6 IU/L lower than those of women with a lower parity (1 
to 2 births) and a younger age at first birth (24 or less). Number of miscarriages was also 
inversely correlated with FSH levels. Women reporting a long durations of OC and HT 
use each had significantly higher mean FSH levels than women who had never used OCs 
or HT. Importantly, these associations existed after adjustment for sex steroids, adiposity 
measures, plasma lipids, blood pressure, and behavioral factors.  
We found that parity was associated with lower FSH levels, while a long duration of 
OCs and HT was associated with higher FSH levels. Given that both pregnancy and HT 
are associated with estrogen exposure and suppression of FSH, it is surprising that these 
associations are not similar. To our knowledge, an association between reproductive 
factors and FSH, accounting for other factors including adiposity, hormones, and 
behavioral factors, has not been observed before. While two previous studies of 
reproductive factors and FSH levels suggested potential associations of pregnancy 
history, both studies did not account for potential confounding by biochemical and 
clinical factors. Consistent with our results showing lower mean FSH levels among 
parous women, Chubak and et5 found that among 173 postmenopausal, sedentary, 
overweight or obese women, nulliparous women had 19% higher FSH concentrations 
than parous women (p=0.02), even after adjustment for age, body fat, alcohol 
consumption, marital status, race, and number of ovaries remaining. Ness et al6 reported 
11 
 
that among 270 postmenopausal women, pregnancy termination was significantly related 
to a rise in FSH one year after menopause (p=0.03), after adjustment for BMI, education, 
oral contraceptive use, smoking, and alcohol consumption. However, this study focused 
on younger, as opposed to older, postmenopausal women. Consistent with our results, 
both of these studies found no association between age at menarche or age at last menses 
and FSH levels. 
 Postmenopausal FSH levels may an important indicator of future disease risk. 
Inverse associations of postmenopausal FSH levels with risk of T2D had been observed 
in prior studies.1,7,8 In the KIHD population, women with FSH levels above the median 
(50 IU/L) had approximately half the risk of developing T2D over 7 to 9 years of follow-
up than women with lower levels.1 Furthermore, each 1 IU/L increase in FSH was 
associated with a 1.9% lower prevalence of diabetes.  Wang et al8 found that participants 
with FSH levels of 50.2 IU/L or less had three times the risk of prevalent diabetes than 
women with FSH levels of at least 82.5 IU/. Bjørnerem et al7 found that women with 
diabetes had geometric mean postmenopausal FSH levels than were 7.4 IU/L lower than 
levels healthy postmenopausal women (P=0.03).  
When combined with results from previous studies, our results of lower FSH 
levels among women with a high parity suggest that women with higher parity have a 
higher risk of T2D. Based on the approximately 7 IU/L difference in FSH levels between 
higher and lower parity women in our population, we would hypothesize that this 
magnitude of difference would translate into a 13% lower diabetes risk (e.g., 7 IU/L* 
1.9% decreased risk per unit).  This is consistent with findings from multiple studies that 
show that a high parity is associated with an increased risk of T2D.9–15 Most recently, 
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Luo et al9 observed than women with five or more live births had 1.13 times the risk of 
incident T2D compared to nulliparous women. 
 Hormone therapy use has been associated with lower diabetes risk in previous 
studies. Pentti et al16 found that among 8483 postmenopausal women, past HT users had 
a 19% lower risk of T2D (95% CI 0.57-1.16) and women who continuously used HT 
during the follow-up period had a 69% lower risk of T2D (95% CI 0.16-0.60) compared 
to never-users. Randomized trials17,18 have also shown that hormone therapy in 
postmenopausal women is associated with a significantly lower incidence of T2D 
compared to non-users, possibly mediated by a reduction in insulin resistance.17 These 
findings are consistent with our results that a longer duration of HT is associated with 
increased FSH levels and with results from previous studies that higher FSH levels are 
associated with lower risk of T2D.1 Previous studies have shown that OC use is not 
associated or is associated with an increased T2D risk. This association is opposite that of 
HT and is not consistent with our findings relating a long duration of OC use to higher 
FSH levels.  
Inverse associations of FSH with insulin suggest that FSH may be related to TD2 
through insulin resistance. Laboratory studies have observed FSH and/or FSH receptor 
activity in extragonadal tissues, suggesting that actions of FSH may extend beyond its 
functions in reproduction. Chu et al19 identified FSH in the rat pancreas, reporting 
coexpression of FSH and FSH receptors in islet cells. FSH altered insulin and glucagon 
secretion by pancreatic cells in vitro in a U-shaped manner. It is unknown whether FSH 
may affect pancreatic insulin secretion in humans, and whether actions may vary by 
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menopausal status. Effects of pregnancy on insulin sensitivity suggest that parity may be 
related to T2D through the association of FSH and insulin.   
 The associations we observed between reproductive factors and FSH levels could 
plausibly be explained by confounding by adiposity, as higher adiposity is associated 
with higher endogenous estrogen production and consequently lower FSH levels. 
However, since we adjusted for both BMI and waist to hip ratio, confounding by 
adiposity and associations of adiposity with estrogens is unlikely to explain our findings. 
Results from our stratified analyses do not give any indication that associations are 
impacted by BMI or only observed among overweight and obese women. 
Our study assessed FSH at a single time point and thus could not assess within-
women variation in FSH. However, this limitation is unlikely to explain our findings, as 
we would expect misclassification relating to the use of a single FSH measure to 
attenuate association rather than exaggerate them. Because the KIHD study population is 
very homogenous with respect to race and ethnicity, additional evaluation of these 
relationships in diverse populations is needed. A strength of our study is the extensive 
data on biochemical, behavioral, and clinical factors, allowing us to adjust beta estimates 
for the effect of a large number of  potential confounders. Associations persisted after 
adjustment, suggesting that associations for FSH are not explained by these factors or by 
other sex steroids. There may be residual confounding if some of the data on the 
confounders is misclassified. As the women are 53 and older, some of the historical data 
may be recalled incorrectly and some current data may be inaccurately reported. 
However, since the covariates that are most likely to be confounders, including estradiol, 
14 
 
testosterone, SHBG, and BMI were directly measured, confounding is unlikely to be an 
issue.   
To our knowledge, this is the first study of multiple reproductive factors and 
postmenopausal FSH levels that accounted for other factors including adiposity, 
hormones, and behavioral factors. We observed evidence of significantly lower FSH 
levels among women with both a high parity and a later age at first birth, and significant 
higher FSH levels among with with a long duration of OC or HT use. Number of 
miscarriages was inversely associated with FSH levels. These associations were not 
explained by estradiol, adiposity, and other factors. Additional studies of reproductive 
factors and FSH in older postmenopausal women are needed to explore potential 
underlying physiological explanations, and whether FSH also underlies associations of 
reproductive factors with diabetes risk.  
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P  value for mean
n Mean SD Min Median Max IQR for mean
53-56 114 54.7 25.3 1.5 53.9 136.8 31.8 0.09
59-62 130 51.6 18.8 2.4 50.9 108.6 20.9
64-68 163 51.3 16.0 4.8 49.4 102.8 17.0
71-73 181 48.9 17.0 3.6 47.0 99.1 23.2
Abbreviations: SD, standard deviation; IQR, interquartile range.
Table 1: Follicle-stimulating hormone levels among women who were 
not currently using hormone therapy, by age group, Kuopio Ischaemic 
Heart Disease Risk Factor Study, 1998-2001
Follicle Simulating Hormone Level, IU/L
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n β (SE) P  value
Year of enrollment
1998 164 3.28 (1.95) 0.09
1999 220 0 (Referent)
2000 186 5.49 (1.88) 0.004
2001 18 14.55 (4.63) 0.002
Age, years 588 -0.29 (0.12) 0.02
Age, years
53-56 114 0 (Referent)
59-62 130 -2.82 (2.44) 0.25
64-68 163 -3.34 (2.32) 0.15
71-73 181 -5.78 (2.27) 0.01
Body mass index
a
588 -1.03 (0.14) <0.0001
Body mass index
Under/normal 147 0 (Referent)
Overweight 225 -5.50 (1.95) 0.005
Obese 216 -13.09 (1.97) <0.0001
Waist:hip ratio 587 -64.56 (12.23) <0.0001
quartile 1 146 0 (Referent)
quartile 2 147 -4.17 (2.17) 0.06
quartile 3 147 -7.72 (2.17) 0.0004
quartile 4 147 -10.32 (2.17) <0.0001
Physical activity, MET h/d 588 0.20 (0.12) 0.09
Alcohol intake, g/week 585 -0.02 (0.02) 0.31
Pack-years of smoking
b
581 -0.07 (0.12) 0.57
Current smoking
no 537 0 (Referent)
yes 49 -2.18 (2.85) 0.44
588 -0.13 (0.04) 0.004
588 -0.09 (0.09) 0.30
Triglycerides, mmol/L 588 -3.72 (1.18) 0.002
HDL cholesterol, mmol/L 587 10.79 (2.47) <0.0001
LDL cholesterol, mmol/L 586 1.86 (0.87) 0.03
Estradiol, pmol/L 588 -0.13 (0.02) <0.0001
Testosterone, nmol/L 588 -2.01 (0.51) <0.0001
580 0.16 (0.03) <0.0001
a
Weight (kg)/height (m)
2
.
b
Pack-years of cigarette smoking among ever smokers
Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein; MET, metabolic 
equivalent of task.
Table 2. Association of baseline characteristics with follicle-stimulating hormone levels 
among women aged 53-73 years who were not using hormone therapy, Kuopio Ischemic Heart 
Disease Risk Factor Study, 1998-2001
Follicle-Stimulating Hormone Level, IU/L
Systolic blood pressure, mm Hg
Diastolic blood pressure, mm Hg
Sex hormone-binding globulin, nmol/L
17 
 
 
n β (SE) P  Value β (SE) P  Value β (SE) P  Value
587 -1.24 (0.47) 0.009 -0.92 (0.43) 0.04 -0.94 (0.44) 0.03
Parity, no. full-term pregnancies
76 1.89 (2.61) 0.47 2.52 (2.44) 0.30 2.12 (2.44) 0.39
94 0.65 (2.43) 0.79 2.09 (2.23) 0.35 1.06 (2.24) 0.64
175 0 (Referent) 0 (Referent) 0 (Referent)
128 -5.50 (2.21) 0.01 -4.01 (2.04) 0.05 -3.18 (2.05) 0.12
114  -3.25 (2.28) 0.16 -0.81 (2.18) 0.71 -2.11 (2.24) 0.35
0.006 0.02 0.02
Age at first birth, years 507 -0.34 (0.19) 0.07 -0.23 (0.17) 0.18 -0.31 (0.17) 0.07
Age at first birth, years
50 0.53 (2.97) 0.86 -0.85 (2.69) 0.75 -0.63 (2.68) 0.81
253 0 (Referent) 0 (Referent) 0 (Referent)
145 -2.49 (2.00) 0.21 -1.90 (1.80) 0.29 -2.52 (1.80) 0.16
59 -4.92 (2.77) 0.08 -3.40 (2.49) 0.17 -4.33 (2.52) 0.09
0.04 0.16 0.06
76 -1.24 (2.71) 0.65 -0.11 (2.52) 0.96 -0.45 (2.52) 0.86
132 0 (Referent) 0 (Referent) 0 (Referent)
171 -6.35 (2.18) 0.004 -3.77 (2.03) 0.06 -3.99 (2.04) 0.05
135 -5.42 (2.30) 0.02 -2.83 (2.10) 0.18 -3.72 (2.11) 0.08
69 -9.69 (2.79) 0.0006 -7.33 (2.61) 0.01 -7.65 (2.59) 0.003
Miscarriages, number 586 -2.74 (1.22) 0.03 -2.87 (1.11) 0.01 -2.92 (1.13) 0.01
Abortions, number 581 0.92 (1.89) 0.63 -0.70 (1.72) 0.68 -0.40 (1.73) 0.82
Abbreviations: SE, standard error.
a
Model 1 unadjusted.   
P  for trend
Table 3. Association of reproductive factors with follicle-stimulating hormone levels (IU/L) among women aged 53-73 years who were not using hormone 
therapy, Kuopio Ischemic Heart Disease Risk Factor Study, 1998-2001
Model 
Model 1
a
Model 2
b
Model 3
c
Parity, no. full-term pregnancies
0
1
2
3
4+
c
Model 3 further adjusted for body mass index (weight (kg)/height (m)
2
), body mass index (WHO categories), waist:hip ratio (quartiles), physical activity 
(MET-hours/day), alcohol intake (g/week), pack-years of smoking (continuous), current smoking (yes,no), systolic and diastolic blood pressure (mm HG; 
continuous), triglycerides (mmol/L), high-density lipoprotein cholesterol (mmol/L), low-density lipoprotein cholesterol (mmol/L).
<20
20-24
25-29
30+
P  for trend
Parity/age at first birth, years
b
Model 2 adjusted for year of enrollment, age (years), age (4 categories), estradiol (pmol/L), testosterone (nmol/L), and sex hormone binding-globulin 
(nmol/L). 
0 births
1-2 births/<25
3+ births/ <25
1-2 births/ 25+
3+ births/ 25+
18 
 
n β (SE) P  Value β (SE) P  Value β (SE) P  Value
History of hysterectomy
448 0 (Referent) 0 (Referent) 0 (Referent)
135 -4.51 (1.86) 0.02 -1.85 (1.72) 0.28 -1.09 (1.73) 0.53
History of oopherectomy
486 0 (Referent) 0 (Referent) 0 (Referent)
85 -1.21 (2.25) 0.59 -1.22 (2.07) 0.56 -0.12 (2.07) 0.95
432 0 (Referent) 0 (Referent) 0 (Referent)
147 -3.21 (1.82) 0.08 -1.53 (1.67) 0.36 -0.79 (1.67) 0.64
Endometriosis
525 0 (Referent) 0 (Referent) 0 (Referent)
38 3.73 (3.23) 0.25 0.70 (2.94) 0.81 0.39 (2.99) 0.90
Uterine myomas
398 0 (Referent) 0 (Referent) 0 (Referent)
178 -3.25 (1.71) 0.06 -1.63 (1.57) 0.30 -0.94 (1.58) 0.55
Abbreviations: SE, standard error.
a
Model 1 unadjusted.   
No
Yes
No
Yes
c
Model 3 further adjusted for  body mass index (weight (kg)/height (m)
2
), body mass index (WHO categories), waist:hip ratio 
(quartiles), physical activity (MET-hours/day), alcohol intake (g/week), pack-years of smoking (continuous), current smoking 
(yes,no), systolic and diastolic blood pressure (mm HG; continuous), triglycerides (mmol/L), high-density lipoprotein 
cholesterol (mmol/L), low-density lipoprotein cholesterol (mmol/L).
b
Model 2 adjusted for year of enrollment, age (years), age (4 categories), estradiol (pmol/L), testosterone (nmol/L), and sex 
hormone binding-globulin (nmol/L). 
Yes
Table 4. Association of reproductive factors with follicle-stimulating hormone levels among women aged 53-73 years who 
were not using hormone therapy, Kuopio Ischemic Heart Disease Risk Factor Study, 1998-2001
Model 
Model 1
a
Model 2
b
Model 3
c
No
Yes
No
Yes
History of gynaceological surgery
No
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n β (SE) P  Value β (SE) P  Value β (SE) P  Value
Age at menarche, years 580 0.25 (0.52) 0.07 (0.47) 0.89 -0.28 (0.47) 0.56
Age at menarche, years
105 -0.18 (2.47) 0.94 1.43 (2.25) 0.52 1.57 (2.27) 0.49
140 0 (Referent) 0 (Referent) 0 (Referent)
128 -0.33 (2.34) 0.89 -0.08 (2.13) 0.97 -1.42 (2.13) 0.51
113 -1.19 (2.42) 0.62 -0.31 (2.20) 0.89 -1.21 (2.21) 0.58
94 1.93 (2.55) 0.45 2.00 (2.31) 0.39 0.49 (2.31) 0.83
0.66 0.89 0.51
Age at last menses, years 569 -0.15 (0.18) 0.40 -0.06 (0.16) 0.73 -0.14 (0.16) 0.38
Age at last menses, years
257 2.58 (1.79) 0.15 1.52 (1.62) 0.35 2.48 (1.63) 0.13
204 0 (Referent) 0 (Referent) 0 (Referent)
127 -0.40 (2.16) 0.85 -0.31 (1.96) 0.87 0.08 (1.97) 0.97
0.09 0.26 0.11
398 0 (Referent) 0 (Referent) 0 (Referent)
179 2.08 (1.72) 0.23 1.67 (1.70) 0.33 2.07 (1.73) 0.23
Duration OC use, years
398 0 (Referent) 0 (Referent) 0 (Referent)
38 1.38 (3.24) 0.67 0.85 (3.10) 0.78 -0.10 (3.23) 0.97
65 0.94 (2.55) 0.71 2.39 (2.42) 0.32 3.14 (2.41) 0.19
41 -1.27 (3.13) 0.69 -1.93 (2.89) 0.50 -2.13 (2.89) 0.46
35 8.90 (3.36) 0.01 5.41 (3.12) 0.08 6.79 (3.13) 0.03
0.04 0.23 0.11
Past HT use
396 0 (Referent) 0 (Referent) 0 (Referent)
180 2.14 (1.68) 0.20 1.20 (1.53) 0.43 1.39 (1.54) 0.37
Duration HT use, years
393 0 (Referent) 0 (Referent) 0 (Referent)
56 -0.86 (2.72) 0.75 -1.28 (2.45) 0.60 -0.98 (2.44) 0.69
59 1.04 (2.66) 0.70 -1.94 (2.44) 0.43 -1.12 (2.44) 0.65
31 8.16 (3.55) 0.02 8.12 (3.20) 0.01 8.65 (3.23) 0.01
33 7.28 (3.45) 0.04 7.36 (3.17) 0.02 7.52 (3.21) 0.02
0.005 0.003 0.003
Abbreviations: SE, standard error; OC, oral contraceptive; HT, hormone therapy.
a
Model 1 unadjusted.   
<50
Table 5. Association of reproductive factors with follicle-stimulating hormone levels among women 
aged 53-73 years who were not using hormone therapy, Kuopio Ischemic Heart Disease Risk Factor 
Study, 1998-2001
Model 
Model 1
a
Model 2
b
Model 3
c
<12
13
14
15
16+
P  for trend
No
50-52
>52
History of OC use
No
Yes
0
<1
1-3
4-6
7+
P  for trend
P  for trend
b
Model 2 adjusted for year of enrollment, age (years), age (4 categories), estradiol (pmol/L), 
testosterone (nmol/L), and sex hormone binding-globulin (nmol/L). 
P  for trend
c
Model 3 further adjusted for body mass index (weight (kg)/height (m)
2
), body mass index (WHO 
categories), waist:hip ratio (quartiles), physical activity (MET-hours/day), alcohol intake (g/week), pack-
years of smoking (continuous), current smoking (yes,no), systolic and diastolic blood pressure (mm HG; 
continuous), triglycerides (mmol/L), high-density lipoprotein cholesterol (mmol/L), low-density 
lipoprotein cholesterol (mmol/L).
Yes
0
<1
1-3
4-6
7+
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n β (SE)
a
P  value n β (SE)
a
P  value
244 -2.64 (1.00) 0.01 343 -0.44 (0.48) 0.35
Parity, no. full-term pregnancies
22 6.79 (4.59) 0.14 54 1.08 (2.97) 0.72
37 0.25 (3.79) 0.95 57 1.90 (2.91) 0.51
107 0 (Referent) 68 0 (Referent)
54 -8.51 (3.37) 0.01 74 1.36 (2.71) 0.62
24 -5.76 (4.53) 0.20 90 -0.58 (2.73) 0.83
Age at first birth, years 221 -0.58 (0.32) 0.07 286 -0.15 (0.20) 0.46
Age at first birth, years
23 -6.16 (4.53) 0.18 27 3.89 (3.35) 0.25
119 0 (Referent) 134 0 (Referent)
51 -7.46 (3.32) 0.03 94 0.39 (2.10) 0.85
28 -7.31 (4.29) 0.09 31 -1.65 (3.14) 0.60
Parity/age at first birth, years
22 2.92 (4.65) 0.53 54 0.95 (3.04) 0.75
79 0 (Referent) 53 0 (Referent)
63 -9.21 (3.30) 0.006 108 1.41 (2.70) 0.60
64 -8.39 (3.32) 0.012 71 1.73 (2.84) 0.54
15 -18.71 (5.44) 0.0007 54 -1.34 (3.05) 0.66
History of OC use
120 0 (Referent) 278 0 (Referent)
120 1.92 (2.70) 0.48 59 3.27 (2.41) 0.17
Duration OC use, years
120 0 (Referent) 278 0 (Referent)
29 1.63 (4.61) 0.72 9 0.52 (5.70) 0.93
40.000 1.86 (3.76) 0.62 25 5.17 (3.29) 0.12
27 -3.15 (4.27) 0.46 14 -1.33 (4.38) 0.76
24 7.48 (4.46) 0.10 11 7.10 (5.23) 0.18
Past HT Use
162 0 (Referent) 234 0 (Referent)
80 -2.43 (2.68) 0.37 100 4.42 (1.89) 0.02
Duration HT use, years
158 0 (Referent) 235 0 (Referent)
26 -5.70 (4.15) 0.17 30 3.79 (2.99) 0.21
21 -10.47 (4.80) 0.03 38 4.47 (2.78) 0.11
20 3.73 (4.68) 0.43 11 12.73 (4.88) 0.01
15 10.83 (5.52) 0.05 18 4.15 (3.90) 0.29
Abbreviations: SE, standard error; OC, oral contraceptive; HT, hormone therapy.
1-3
4-6
7+
a
Results adjusted for year of enrollment, body mass index (weight (kg)/height (m)
2
), body mass index (WHO 
categories), waist:hip ratio (quartiles), physical activity (MET-hours/day), alcohol intake (g/week), pack-years 
of smoking (continuous), current smoking (yes,no), systolic and diastolic blood pressure (mm HG; 
continuous), triglycerides (mmol/L), high-density lipoprotein cholesterol (mmol/L), low-density lipoprotein 
cholesterol (mmol/L), estradiol (pmol/L), testosterone (nmol/L), and sex hormone binding-globulin (nmol/L).
4-6
7+
No
Yes
0
<1
1-3
25-29
30+
0 births
1-2 births/<25
3-4 births/ <25
1-2 births/ 25+
3-4 births/ 25+
No
Yes
0
< 1 
20-24
Table 6. Association of reproductive factors with follicle-stimulating hormone levels among women aged 53-
73 years who were not using hormone therapy, stratified by age group, Kuopio Ischemic Heart Disease Risk 
Factor Study, 1998-2001
Age Group
53-62 Years 64-73 Years
Parity, no. full-term pregnancies
0
1
2
3
4+
<20
21 
 
β (SE)b P  value β (SE)b P  value β (SE)b P  value
-0.76 (1.26) 0.55 -1.37 (0.68) 0.04 -0.94 (0.68) 0.17
Parity, no. full-term pregnancies
-4.82 (6.45) 0.46 2.84 (3.98) 0.48 6.55 (3.88) 0.09
-1.05 (4.97) 0.83 0.97 (3.97) 0.81 1.21 (3.65) 0.74
0 (Referent) 0 (Referent) 0 (Referent)
-11.92 (5.68) 0.04 -2.63 (3.01) 0.43 -1.41 (3.11) 0.65
-2.70 (5.54) 0.63 -5.27 (4.01) 0.19 0.22 (3.37) 0.95
Age at first birth, years -0.30 (0.45) 0.51 -0.52 (0.27) 0.06 -0.20 (0.28) 0.47
Age at first birth, years
-14.19 (7.43) 0.06 1.39 (4.23) 0.74 3.23 (4.32) 0.46
0 (Referent) 0 (Referent) 0 (Referent)
-10.79 (4.55) 0.02 0.89 (2.96) 0.76 -2.42 (2.86) 0.40
-4.68 (6.09) 0.44 -8.12 (4.12) 0.050 -2.83 (3.90) 0.47
Parity/age at first birth, years
-8.89 (6.38) 0.17 1.84 (4.21) 0.66 2.90 (3.96) 0.46
0 (Referent) 0 (Referent) 0 (Referent)
-8.23 (5.33) 0.13 -3.28 (3.55) 0.36 -4.16 (3.13) 0.18
-7.77 (4.75) 0.10 -1.19 (3.75) 0.75 -6.12 (3.39) 0.07
-16.87 (6.51) 0.01 -7.21 (4.35) 0.10 -4.81 (4.08) 0.24
Miscarriages, number -2.38 (2.16) 0.27 -5.16 (2.15) 0.02 -2.48 (1.92) 0.20
Abortions, number 7.46 (4.34) 0.09 -1.61 (2.81) 0.57 -3.49 (2.75) 0.21
0 (Referent) 0 (Referent) 0 (Referent)
-4.23 (5.02) 0.40 -1.38 (2.70) 0.61 2.29 (2.64) 0.39
History of oopherectomy
0 (Referent) 0 (Referent) 0 (Referent)
-3.39 (5.88) 0.57 -0.34 (3.22) 0.92 2.96 (3.23) 0.36Yes
1-2 births/ 25+
3-4 births/ 25+
History of hysterectomy
No
Yes
No
3-4 births/ <25
0
1
2
3
4+
<20
20-24
25-29
30+
0 births
1-2 births/<25
Parity, no. full-term pregnancies
Table 7. Association of reproductive factors with follicle-stimulating hormone levels among women aged 53-73 years who were not using hormone 
therapy, stratified by Body Mass Index, Kuopio Ischemic Heart Disease Risk Factor Study, 1998-2001
Body Mass Index
a
<25.0 (Normal-Weight, n=147) 25.0-29.9 (Overweight, n=225) ≥ 30.0 (obese, n=216)
22 
 
β (SE)b P  value β (SE)b P  value β (SE)b P  value
History of gynaceological surgery
0 (Referent) 0 (Referent) 0 (Referent)
-2.91 (4.79) 0.54 -1.80 (2.58) 0.49 2.51 (2.64) 0.34
Endometriosis
0 (Referent) 0 (Referent) 0 (Referent)
Age at menarche, years -2.17 (1.13) 0.06 0.40 (0.83) 0.63 0.28 (0.77) 0.72
Age at menarche, years
-1.05 (6.04) 0.86 2.08 (3.99) 0.60 3.12 (3.31) 0.35
0 (Referent) 0 (Referent) 0 (Referent)
-11.35 (5.41) 0.04 -0.72 (3.38) 0.83 0.37 (3.47) 0.91
-8.97 (5.37) 0.10 -4.47 (3.76) 0.24 4.76 (3.49) 0.17
-12.56 (5.38) 0.02 5.85 (3.59) 0.10 2.93 (4.21) 0.49
Age at last menses, years -0.02 (0.46) 0.97 0.08 (0.25) 0.74 -0.40 (0.26) 0.12
Age at last menses, years
-3.31 (3.97) 0.41 2.57 (2.68) 0.34 6.71 (2.53) 0.01
0 (Referent) 0 (Referent) 0 (Referent)
-3.00 (5.03) 0.55 1.48 (3.31) 0.66 1.54 (2.87) 0.59
History of OC use
0 (Referent) 0 (Referent) 0 (Referent)
6.50 (4.30) 0.13 -0.58 (2.86) 0.84 3.68 (2.77) 0.18
Duration OC use
0 (Referent) 0 (Referent) 0 (Referent)
8.67 (7.83) 0.27 -8.74 (5.22) 0.10 7.62 (5.24) 0.15
7.72 (6.61) 0.25 3.37 (3.89) 0.39 3.06 (3.77) 0.42
2.48 (6.19) 0.69 -5.24 (4.94) 0.29 -4.21 (5.12) 0.41
10.13 (7.74) 0.19 4.47 (5.42) 0.41 8.82 (4.94) 0.08
Past HT Use
0 (Referent) 0 (Referent) 0 (Referent)
9.25 (3.71) 0.01 -2.22 (2.54) 0.38 1.77 (2.48) 0.48Yes
0
< 1 
1-3
4-6
7+
No
Yes
Yes
No
<12
13
14
15
16+
<50
50-52
>52
No
No
Table 7 Continued. 
Body Mass Index
a
<25.0 (Normal-Weight, n=147) 25.0-29.9 (Overweight, n=225) ≥ 30.0 (obese, n=216)
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β (SE)b P  value β (SE)b P  value β (SE)b P  value
Duration HT use, years
0 (Referent) 0 (Referent) 0 (Referent)
0.84 (6.34) 0.89 -5.33 (4.08) 0.19 2.17 (3.49) 0.53
13.59 (5.55) 0.02 -6.99 (3.98) 0.08 -3.92 (4.13) 0.34
30.70 (7.28) <0.0001 0.23 (4.98) 0.96 3.72 (5.70) 0.51
1.68 (7.42) 0.82 6.4 (4.25) 0.13 14.80 (8.36) 0.08
Abbreviations: SE, standard error; OC, oral contraceptive; HT, hormone therapy.
b
Results were adjusted for year of enrollment, age (years), age (4 categories), waist:hip ratio (quartiles), physical activity (MET-hours/day), alcohol 
intake (g/week), pack-years of smoking (continuous), current smoking (yes,no), systolic and diastolic blood pressure (mm HG; continuous), 
triglycerides (mmol/L), high-density lipoprotein cholesterol (mmol/L), low-density lipoprotein cholesterol (mmol/L), estradiol (pmol/L), 
testosterone (nmol/L), and sex hormone binding-globulin (nmol/L).    
Table 7 Continued.
Body Mass Index
a
<25.0 (Normal-Weight, n=147) 25.0-29.9 (Overweight, n=225) ≥ 30.0 (obese, n=216)
0
<1
1-3
4-6
7+
a
Weight (kg)/height (m)
2
.
24 
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